Please assess the completion status of the following clinical trial:

Trial Title: Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Benign Prostatic Hyperplasia, based on medical history~* Voiding symptoms~* Uroflow (max) 5-15mL/sec~Exclusion Criteria:~* Urgent need for prostate surgery~* History of allergic reaction to peptide~* Major organ dysfunction~* Prior surgical treatment of the prostate or bladder~* Current or recent treatment with sexual hormone drugs or 5 α reductase inhibitors or botulinum toxin type a (Botox) within the last 6 months prior to trial medication at Week 0 or with α blockers or saw palmetto within the last 6 weeks prior to trial medication at Week 0~* Urologic disorders including neurogenic bladder dysfunction due to diabetes mellitus or documented neurologic disorder, urethral stricture disease or history of pelvic radiation therapy~* History of acute obstructive, infectious, or neurological disorders of the genitourinary tract within the last 3 months

- Gender: MALE
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cetrorelix 78 mg (Type: EXPERIMENTAL): Drug: Cetrorelix 52 mg week 0, and 26 mg week 2, intra muscular-2 doses in 2 weeks and follow up to week 26.

Based on this trial design, predict the completion outcome and termination type (if applicable).